tradingkey.logo

Grifols SA

GRFS
查看詳細走勢圖
9.140USD
+0.120+1.33%
交易中 美東報價延遲15分鐘
2.35B總市值
15.04本益比TTM

Grifols SA

9.140
+0.120+1.33%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.33%

5天

0.00%

1月

+8.81%

6月

+4.22%

今年開始到現在

+22.85%

1年

+21.70%

查看詳細走勢圖

TradingKey Grifols SA股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Grifols SA當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在藥品行業排名63/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價12.20。中期看,股價處於平穩狀態。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Grifols SA評分

相關信息

行業排名
63 / 158
全市場排名
150 / 4582
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 8 分析師
買入
評級
12.200
目標均價
+35.86%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Grifols SA亮點

亮點風險
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
業績高增長
公司營業收入穩步增長,連續3年增長22.33%
估值低估
公司最新PE估值14.84,處於3年歷史低位
機構減倉
最新機構持股150.82M股,環比減少7.67%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉1.91K股

Grifols SA新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Grifols SA簡介

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
公司代碼GRFS
公司Grifols SA
CEOAbia (Jose Ignacio)
網址https://www.grifols.com/

常見問題

Grifols SA(GRFS)的當前股價是多少?

Grifols SA(GRFS)的當前股價是 9.140。

Grifols SA 的股票代碼是什麼?

Grifols SA的股票代碼是GRFS。

Grifols SA股票的52週最高點是多少?

Grifols SA股票的52週最高點是11.140。

Grifols SA股票的52週最低點是多少?

Grifols SA股票的52週最低點是6.190。

Grifols SA的市值是多少?

Grifols SA的市值是2.35B。

Grifols SA的淨利潤是多少?

Grifols SA的淨利潤為169.72M。

現在Grifols SA(GRFS)的股票是買入、持有還是賣出?

根據分析師評級,Grifols SA(GRFS)的總體評級為買入,目標價格為12.200。

Grifols SA(GRFS)股票的每股收益(EPS TTM)是多少

Grifols SA(GRFS)股票的每股收益(EPS TTM)是0.608。
KeyAI